Outpatient management of partial-thickness burns: Biobrane ® versus 1% silver sulfadiazine
A randomized, prospective study comparing the use of Biobrane ® (group 1) with the use of 1% silver sulfadiazine (group 2) in treating 56 partial-thickness burn wounds was carried out in 52 outpatients with burns that comprised less than 10% of their total body surface area. The two groups were simi...
Gespeichert in:
| Veröffentlicht in: | Annals of emergency medicine 1990-02, Vol.19 (2), p.121-124 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 124 |
|---|---|
| container_issue | 2 |
| container_start_page | 121 |
| container_title | Annals of emergency medicine |
| container_volume | 19 |
| creator | Gerding, Robert L Emerman, Charles L Effron, David Lukens, Thomas Imbembo, Anthony L Fratianne, Richard B |
| description | A randomized, prospective study comparing the use of Biobrane
® (group 1) with the use of 1% silver sulfadiazine (group 2) in treating 56 partial-thickness burn wounds was carried out in 52 outpatients with burns that comprised less than 10% of their total body surface area. The two groups were similar in age, gender, race, and extent of burn. Wounds of patients in group 1 (30) were compared with those of group 2 (26) for healing time, pain, compliance with scheduled visits, and costs. Infected and skin-grafted wounds were excluded from healing time analysis. Infection rates of the two groups were similar (three of 30 vs two of 26). One patient in each group underwent skin grafting. Healing times of group 1 wounds were significantly less than those of group 2 (10.6 ± 0.8 vs 15.0 ± 1.2 days,
P < .01). Using a pain scale of 1 to 5, Biobrane
®-treated patients averaged lower pain scores at 24 hours after the burn (1.6 ± 0.8 vs 3.6 ± 1.3,
P < .001) and used less pain medication. Compliance with scheduled outpatient visits was also improved in the Biobrane
®-treated group (88.6% vs 63.2% attendance,
P < .001). Idealized total treatment costs averaged $434 for patients in group 1 compared with $504 for patients in group 2. We conclude that when used on properly selected wounds. Biobrane
® therapy can significantly decrease pain and total healing time without increasing the cost of outpatient burn care. Improved patient compliance may be an added benefit. |
| doi_str_mv | 10.1016/S0196-0644(05)81793-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79610232</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196064405817937</els_id><sourcerecordid>79610232</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-8cdd8ee67a64dc937da43616086931ccd059632fcd6fe503f2fdbc82d966fcfb3</originalsourceid><addsrcrecordid>eNqFkEtuFDEQQC0ECkPgCJF6E0QWDeV2226zQRDxkyJlAaxYWG67DIb-TFzdkcihOAQnw5MZhSWrqlK9-ugxdsLhOQeuXnwCblQNqm2fgTzruDai1vfYhoPRtdIK7rPNHfKQPSL6AQCmbfgRO2pakLo1G_b1cl22bkk4LdXoJvcNx106x2rr8pLcUC_fk_85IVHVr3mil9WbNPfZTVj9-V1dY6aVKn5aURpKUdE6RBeSu0kTPmYPohsInxziMfvy7u3n8w_1xeX7j-evL2ovQC5150PoEJV2qg3eCB1cKxRX0CkjuPcBpFGiiT6oiBJEbGLofdcEo1T0sRfH7Ol-7zbPVyvSYsdEHoehPDmvZLVRHBrRFFDuQZ9noozRbnMaXf5lOdidVHsr1e6MWZD2VqrVZe7kcGDtRwx3UweLpX966DvybojFjk_0b7mRIDslC_dqz2GxcZ0wW_LFvMeQMvrFhjn955O_5ImViQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79610232</pqid></control><display><type>article</type><title>Outpatient management of partial-thickness burns: Biobrane ® versus 1% silver sulfadiazine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Gerding, Robert L ; Emerman, Charles L ; Effron, David ; Lukens, Thomas ; Imbembo, Anthony L ; Fratianne, Richard B</creator><creatorcontrib>Gerding, Robert L ; Emerman, Charles L ; Effron, David ; Lukens, Thomas ; Imbembo, Anthony L ; Fratianne, Richard B</creatorcontrib><description>A randomized, prospective study comparing the use of Biobrane
® (group 1) with the use of 1% silver sulfadiazine (group 2) in treating 56 partial-thickness burn wounds was carried out in 52 outpatients with burns that comprised less than 10% of their total body surface area. The two groups were similar in age, gender, race, and extent of burn. Wounds of patients in group 1 (30) were compared with those of group 2 (26) for healing time, pain, compliance with scheduled visits, and costs. Infected and skin-grafted wounds were excluded from healing time analysis. Infection rates of the two groups were similar (three of 30 vs two of 26). One patient in each group underwent skin grafting. Healing times of group 1 wounds were significantly less than those of group 2 (10.6 ± 0.8 vs 15.0 ± 1.2 days,
P < .01). Using a pain scale of 1 to 5, Biobrane
®-treated patients averaged lower pain scores at 24 hours after the burn (1.6 ± 0.8 vs 3.6 ± 1.3,
P < .001) and used less pain medication. Compliance with scheduled outpatient visits was also improved in the Biobrane
®-treated group (88.6% vs 63.2% attendance,
P < .001). Idealized total treatment costs averaged $434 for patients in group 1 compared with $504 for patients in group 2. We conclude that when used on properly selected wounds. Biobrane
® therapy can significantly decrease pain and total healing time without increasing the cost of outpatient burn care. Improved patient compliance may be an added benefit.</description><identifier>ISSN: 0196-0644</identifier><identifier>EISSN: 1097-6760</identifier><identifier>DOI: 10.1016/S0196-0644(05)81793-7</identifier><identifier>PMID: 2405749</identifier><identifier>CODEN: AEMED3</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>1% silver sulfadiazine ; Adolescent ; Adult ; Aged ; Ambulatory Care ; Biobrane ; Biocompatible Materials ; Biological and medical sciences ; burns ; Burns - economics ; Burns - therapy ; Child ; Child, Preschool ; Coated Materials, Biocompatible ; Costs and Cost Analysis ; Female ; Humans ; Infant ; Male ; Medical sciences ; Middle Aged ; Occlusive Dressings ; Pain - physiopathology ; Patient Compliance ; Pharmacology. Drug treatments ; Prospective Studies ; Randomized Controlled Trials as Topic ; Silver Sulfadiazine - therapeutic use ; Skin, nail, hair, dermoskeleton ; Sulfadiazine - therapeutic use ; Wound Healing</subject><ispartof>Annals of emergency medicine, 1990-02, Vol.19 (2), p.121-124</ispartof><rights>1990 American College of Emergency Physicians</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-8cdd8ee67a64dc937da43616086931ccd059632fcd6fe503f2fdbc82d966fcfb3</citedby><cites>FETCH-LOGICAL-c305t-8cdd8ee67a64dc937da43616086931ccd059632fcd6fe503f2fdbc82d966fcfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0196-0644(05)81793-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19505865$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2405749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gerding, Robert L</creatorcontrib><creatorcontrib>Emerman, Charles L</creatorcontrib><creatorcontrib>Effron, David</creatorcontrib><creatorcontrib>Lukens, Thomas</creatorcontrib><creatorcontrib>Imbembo, Anthony L</creatorcontrib><creatorcontrib>Fratianne, Richard B</creatorcontrib><title>Outpatient management of partial-thickness burns: Biobrane ® versus 1% silver sulfadiazine</title><title>Annals of emergency medicine</title><addtitle>Ann Emerg Med</addtitle><description>A randomized, prospective study comparing the use of Biobrane
® (group 1) with the use of 1% silver sulfadiazine (group 2) in treating 56 partial-thickness burn wounds was carried out in 52 outpatients with burns that comprised less than 10% of their total body surface area. The two groups were similar in age, gender, race, and extent of burn. Wounds of patients in group 1 (30) were compared with those of group 2 (26) for healing time, pain, compliance with scheduled visits, and costs. Infected and skin-grafted wounds were excluded from healing time analysis. Infection rates of the two groups were similar (three of 30 vs two of 26). One patient in each group underwent skin grafting. Healing times of group 1 wounds were significantly less than those of group 2 (10.6 ± 0.8 vs 15.0 ± 1.2 days,
P < .01). Using a pain scale of 1 to 5, Biobrane
®-treated patients averaged lower pain scores at 24 hours after the burn (1.6 ± 0.8 vs 3.6 ± 1.3,
P < .001) and used less pain medication. Compliance with scheduled outpatient visits was also improved in the Biobrane
®-treated group (88.6% vs 63.2% attendance,
P < .001). Idealized total treatment costs averaged $434 for patients in group 1 compared with $504 for patients in group 2. We conclude that when used on properly selected wounds. Biobrane
® therapy can significantly decrease pain and total healing time without increasing the cost of outpatient burn care. Improved patient compliance may be an added benefit.</description><subject>1% silver sulfadiazine</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Ambulatory Care</subject><subject>Biobrane</subject><subject>Biocompatible Materials</subject><subject>Biological and medical sciences</subject><subject>burns</subject><subject>Burns - economics</subject><subject>Burns - therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Coated Materials, Biocompatible</subject><subject>Costs and Cost Analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Occlusive Dressings</subject><subject>Pain - physiopathology</subject><subject>Patient Compliance</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Silver Sulfadiazine - therapeutic use</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Sulfadiazine - therapeutic use</subject><subject>Wound Healing</subject><issn>0196-0644</issn><issn>1097-6760</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtuFDEQQC0ECkPgCJF6E0QWDeV2226zQRDxkyJlAaxYWG67DIb-TFzdkcihOAQnw5MZhSWrqlK9-ugxdsLhOQeuXnwCblQNqm2fgTzruDai1vfYhoPRtdIK7rPNHfKQPSL6AQCmbfgRO2pakLo1G_b1cl22bkk4LdXoJvcNx106x2rr8pLcUC_fk_85IVHVr3mil9WbNPfZTVj9-V1dY6aVKn5aURpKUdE6RBeSu0kTPmYPohsInxziMfvy7u3n8w_1xeX7j-evL2ovQC5150PoEJV2qg3eCB1cKxRX0CkjuPcBpFGiiT6oiBJEbGLofdcEo1T0sRfH7Ol-7zbPVyvSYsdEHoehPDmvZLVRHBrRFFDuQZ9noozRbnMaXf5lOdidVHsr1e6MWZD2VqrVZe7kcGDtRwx3UweLpX966DvybojFjk_0b7mRIDslC_dqz2GxcZ0wW_LFvMeQMvrFhjn955O_5ImViQ</recordid><startdate>199002</startdate><enddate>199002</enddate><creator>Gerding, Robert L</creator><creator>Emerman, Charles L</creator><creator>Effron, David</creator><creator>Lukens, Thomas</creator><creator>Imbembo, Anthony L</creator><creator>Fratianne, Richard B</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199002</creationdate><title>Outpatient management of partial-thickness burns: Biobrane ® versus 1% silver sulfadiazine</title><author>Gerding, Robert L ; Emerman, Charles L ; Effron, David ; Lukens, Thomas ; Imbembo, Anthony L ; Fratianne, Richard B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-8cdd8ee67a64dc937da43616086931ccd059632fcd6fe503f2fdbc82d966fcfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>1% silver sulfadiazine</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Ambulatory Care</topic><topic>Biobrane</topic><topic>Biocompatible Materials</topic><topic>Biological and medical sciences</topic><topic>burns</topic><topic>Burns - economics</topic><topic>Burns - therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Coated Materials, Biocompatible</topic><topic>Costs and Cost Analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Occlusive Dressings</topic><topic>Pain - physiopathology</topic><topic>Patient Compliance</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Silver Sulfadiazine - therapeutic use</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Sulfadiazine - therapeutic use</topic><topic>Wound Healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gerding, Robert L</creatorcontrib><creatorcontrib>Emerman, Charles L</creatorcontrib><creatorcontrib>Effron, David</creatorcontrib><creatorcontrib>Lukens, Thomas</creatorcontrib><creatorcontrib>Imbembo, Anthony L</creatorcontrib><creatorcontrib>Fratianne, Richard B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of emergency medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gerding, Robert L</au><au>Emerman, Charles L</au><au>Effron, David</au><au>Lukens, Thomas</au><au>Imbembo, Anthony L</au><au>Fratianne, Richard B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outpatient management of partial-thickness burns: Biobrane ® versus 1% silver sulfadiazine</atitle><jtitle>Annals of emergency medicine</jtitle><addtitle>Ann Emerg Med</addtitle><date>1990-02</date><risdate>1990</risdate><volume>19</volume><issue>2</issue><spage>121</spage><epage>124</epage><pages>121-124</pages><issn>0196-0644</issn><eissn>1097-6760</eissn><coden>AEMED3</coden><abstract>A randomized, prospective study comparing the use of Biobrane
® (group 1) with the use of 1% silver sulfadiazine (group 2) in treating 56 partial-thickness burn wounds was carried out in 52 outpatients with burns that comprised less than 10% of their total body surface area. The two groups were similar in age, gender, race, and extent of burn. Wounds of patients in group 1 (30) were compared with those of group 2 (26) for healing time, pain, compliance with scheduled visits, and costs. Infected and skin-grafted wounds were excluded from healing time analysis. Infection rates of the two groups were similar (three of 30 vs two of 26). One patient in each group underwent skin grafting. Healing times of group 1 wounds were significantly less than those of group 2 (10.6 ± 0.8 vs 15.0 ± 1.2 days,
P < .01). Using a pain scale of 1 to 5, Biobrane
®-treated patients averaged lower pain scores at 24 hours after the burn (1.6 ± 0.8 vs 3.6 ± 1.3,
P < .001) and used less pain medication. Compliance with scheduled outpatient visits was also improved in the Biobrane
®-treated group (88.6% vs 63.2% attendance,
P < .001). Idealized total treatment costs averaged $434 for patients in group 1 compared with $504 for patients in group 2. We conclude that when used on properly selected wounds. Biobrane
® therapy can significantly decrease pain and total healing time without increasing the cost of outpatient burn care. Improved patient compliance may be an added benefit.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>2405749</pmid><doi>10.1016/S0196-0644(05)81793-7</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0196-0644 |
| ispartof | Annals of emergency medicine, 1990-02, Vol.19 (2), p.121-124 |
| issn | 0196-0644 1097-6760 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79610232 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | 1% silver sulfadiazine Adolescent Adult Aged Ambulatory Care Biobrane Biocompatible Materials Biological and medical sciences burns Burns - economics Burns - therapy Child Child, Preschool Coated Materials, Biocompatible Costs and Cost Analysis Female Humans Infant Male Medical sciences Middle Aged Occlusive Dressings Pain - physiopathology Patient Compliance Pharmacology. Drug treatments Prospective Studies Randomized Controlled Trials as Topic Silver Sulfadiazine - therapeutic use Skin, nail, hair, dermoskeleton Sulfadiazine - therapeutic use Wound Healing |
| title | Outpatient management of partial-thickness burns: Biobrane ® versus 1% silver sulfadiazine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outpatient%20management%20of%20partial-thickness%20burns:%20Biobrane%20%C2%AE%20versus%201%25%20silver%20sulfadiazine&rft.jtitle=Annals%20of%20emergency%20medicine&rft.au=Gerding,%20Robert%20L&rft.date=1990-02&rft.volume=19&rft.issue=2&rft.spage=121&rft.epage=124&rft.pages=121-124&rft.issn=0196-0644&rft.eissn=1097-6760&rft.coden=AEMED3&rft_id=info:doi/10.1016/S0196-0644(05)81793-7&rft_dat=%3Cproquest_cross%3E79610232%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79610232&rft_id=info:pmid/2405749&rft_els_id=S0196064405817937&rfr_iscdi=true |